With this approval, Processa Pharmaceuticals is able to move forward with a clinical trial of NGC-Cap. The company says that it expect to start enrolling patients in this study this quarter. David ...

Processa Pharmaceuticals (NASDAQ:PCSA) on Friday priced the public offering of its stock and warrants to raise gross proceeds of up to $7 million. The offering will consist of 1,555,555 shares or ...

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499 ...

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September: H.C.

Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase I for Gastrointestinal Tumor.

HANOVER, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces positive data from preclinical studies that support the potential for NGC-Iri to have ...

Aug. 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...